keyword
MENU ▼
Read by QxMD icon Read
search

Cardiac Chemotherapy

keyword
https://www.readbyqxmd.com/read/28434150/high-sensitive-troponin-t-assay-can-predict-anthracycline-and-trastuzumab-induced-cardiotoxicity-in-breast-cancer-patients
#1
Hiromitsu Kitayama, Tomohiro Kondo, Junko Sugiyama, Kazutomo Kurimoto, Yasuhiro Nishino, Masaya Kawada, Michiaki Hirayama, Yasushi Tsuji
BACKGROUND: Trastuzumab following anthracycline causes cardiotoxicity in up to 28% of patients. Although the cardiotoxicity is often irreversible once cardiac dysfunction is detected, the early predictor has not been established yet. METHODS: We prospectively observed breast cancer patients treated with anthracycline or trastuzumab at Tonan Hospital. All patients underwent echocardiography and blood sampling at baseline, and every three months during chemotherapy...
April 22, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28426104/a-randomized-open-label-phase-iii-trial-comparing-amrubicin-versus-docetaxel-in-patients-with-previously-treated-non-small-cell-lung-cancer
#2
H Yoshioka, N Katakami, H Okamoto, Y Iwamoto, T Seto, T Takahashi, N Sunaga, S Kudoh, K Chikamori, M Harada, H Tanaka, H Saito, H Saka, K Takeda, N Nogami, N Masuda, T Harada, H Kitagawa, H Horio, T Yamanaka, M Fukuoka, N Yamamoto, K Nakagawa
Background: Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a standard treatment for NSCLC, have been reported. Patients and methods: We conducted a randomized phase III trial of Japanese NSCLC patients after one or two chemotherapy regimens. Patients were randomized to amrubicin (35 mg/m2 on days 1-3 every 3 weeks) or docetaxel (60 mg/m2 on day 1 every 3 weeks)...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28424936/preoperative-chemoradiotherapy-versus-perioperative-chemotherapy-for-patients-with-resectable-esophageal-or-gastroesophageal-junction-adenocarcinoma
#3
M C J Anderegg, P C van der Sluis, J P Ruurda, S S Gisbertz, M C C M Hulshof, M van Vulpen, N Haj Mohammed, H W M van Laarhoven, M J Wiezer, M Los, M I van Berge Henegouwen, R van Hillegersberg
BACKGROUND: This study compares neoadjuvant chemoradiotherapy (nCRT) with perioperative chemotherapy (pCT) for patients with resectable esophageal or gastroesophageal junction (GEJ) adenocarcinoma in terms of toxicity, postoperative complications, pathologic response, and survival. METHODS: This study retrospectively analyzed and compared 313 patients with resectable esophageal or GEJ adenocarcinoma treated with either nCRT (carboplatin/paclitaxel 41.4 Gy, n = 176) or pCT (epirubicin, cisplatin and capecitabine, n = 137)...
April 19, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28423723/honokiol-an-activator-of-sirtuin-3-sirt3-preserves-mitochondria-and-protects-the-heart-from-doxorubicin-induced-cardiomyopathy-in-mice
#4
Vinodkumar B Pillai, Abhinav Kanwal, Yong Hu Fang, Willard W Sharp, Sadhana Samant, Jack Arbiser, Mahesh P Gupta
Doxorubicin is the chemotherapeutic drug of choice for a wide variety of cancers, and cardiotoxicity is one of the major side effects of doxorubicin treatment. One of the main cellular targets of doxorubicin in the heart is mitochondria. Mitochondrial sirtuin, SIRT3 has been shown to protect against doxorubicin-induced cardiotoxicity. We have recently identified honokiol (HKL) as an activator of SIRT3, which protects the heart from developing pressure overload hypertrophy. Here, we show that HKL-mediated activation of SIRT3 also protects the heart from doxorubicin-induced cardiac damage without compromising the tumor killing potential of doxorubicin...
March 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28421484/the-role-of-biomarkers-in-detection-of-cardio-toxicity
#5
REVIEW
Kevin S Shah, Eric H Yang, Alan S Maisel, Gregg C Fonarow
The goal of this paper is to review the current literature on the role of biomarkers in the detection and management of patients with cardio-oncologic disease. The role of biomarker surveillance in patients with known cardiac disease, as a result of chemotherapy or with the potential to develop cardio-toxicity, will be discussed. In addition, the studies surrounding sub-clinical cardiac toxicity monitoring during therapy, identification of high-risk patients prior to therapy, and tailoring oncologic therapies to potential biomarker risk profiles are reviewed...
June 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28410144/cardiotoxicity-in-oncology-and-coronary-microcirculation-future-challenges-in-theranostics
#6
Giovanni Peretto, Davide Lazzeroni, Carmem L Sartorio, Paolo G Camici
Many of the patients undergoing chemotherapy or radiotherapy for cancer are at increased risk of developing cardiovascular diseases. Recent evidence suggests that cardiac dysfunction and subsequent heart failure are mainly due to vascular toxicity rather than only to due to myocyte toxicity. However, not all of the vascular toxicity of cancer therapies can be explained by epicardial coronary artery disease. In fact, in the last decades, it has been found that myocardial ischemia may occur as a consequence of structural or functional dysfunction of the complex network of vessels, which cannot be seen by a coronary angiography: the coronary microcirculation...
June 1, 2017: Frontiers in Bioscience (Landmark Edition)
https://www.readbyqxmd.com/read/28409561/the-most-prevalent-side-effects-of-pegylated-liposomal-doxorubicin-monotherapy-in-women-with-metastatic-breast-cancer-a-systematic-review-of-clinical-trials
#7
REVIEW
L Ansari, F Shiehzadeh, Z Taherzadeh, S Nikoofal-Sahlabadi, A A Momtazi-Borojeni, A Sahebkar, S Eslami
Despite benefits of systemic chemotherapy in breast cancer treatment, several patients with early-stage breast cancer will develop metastatic breast cancer (MBC). Doxorubicin is among the most active agents against MBC. However, the use of doxorubicin is related to some life-threatening side effects including cardiotoxicity. Many efforts were made to lessen the side effects of doxorubicin and improve its efficacy. Pegylated liposomal doxorubicin (PLD) is a product claimed to achieve these two objectives because of its different pharmacokinetic profile...
April 14, 2017: Cancer Gene Therapy
https://www.readbyqxmd.com/read/28398124/from-molecular-mechanisms-to-clinical-management-of-antineoplastic-drug-induced-cardiovascular-toxicity-a-translational-overview
#8
Carlo Gabriele Tocchetti, Christian Cadeddu, Daniela Di Lisi, Saveria Femminò, Rosalinda Madonna, Donato Mele, Ines Monte, Giuseppina Novo, Claudia Penna, Alessia Pepe, Paolo Spallarossa, Gilda Varricchi, Concetta Zito, Pasquale Pagliaro, Giuseppe Mercuro
SIGNIFICANCE: Antineoplastic therapies have improved the prognosis of oncology patients sig-nificantly. However, these treatments can bring to a higher incidence of side effects, including the worrying cardiovascular toxicity (CTX). Recent Advances: Substantial evidence indicates multiple mechanisms of CTX, with redox mechanisms playing a key role. Recent data singled out mitochondria as key targets for antineoplastic drug-induced CTX; understanding the underlying mechanisms is therefore cru-cial for effective cardioprotection, without compromising the efficacy of anti-cancer treat-ments...
April 11, 2017: Antioxidants & Redox Signaling
https://www.readbyqxmd.com/read/28395211/antioxidant-and-antiapoptotic-effects-of-sea-cucumber-and-valsartan-against-doxorubicin-induced-cardiotoxicity-in-rats-the-role-of-low-dose-gamma-irradiation
#9
Doaa M Ibrahim, Rasha R Radwan, Salma M Abdel Fattah
Doxorubicin (DOX) is a highly effective antineoplastic drug; however, the clinical use of DOX is limited by its dose dependent cardiotoxicity. This study was conducted to evaluate the cardioprotective effect of sea cucumber and valsartan against DOX-induced cardiotoxicity in rats. Also, the role of exposure to low dose γ radiation (LDR) on each of them was investigated, since LDR could suppress various reactive oxygen species-related diseases. Rats received DOX (2.5mg/kg, ip) in six equal injections over a period of 2weeks, sea cucumber (14...
March 31, 2017: Journal of Photochemistry and Photobiology. B, Biology
https://www.readbyqxmd.com/read/28393216/cancer-induced-cardiac-cachexia-pathogenesis-and-impact-of-physical-activity-review
#10
Yassine Belloum, Françoise Rannou-Bekono, François B Favier
Cachexia is a wasting syndrome observed in many patients suffering from several chronic diseases including cancer. In addition to the progressive loss of skeletal muscle mass, cancer cachexia results in cardiac function impairment. During the severe stage of the disease, patients as well as animals bearing cancer cells display cardiac atrophy. Cardiac energy metabolism is also impeded with disruption of mitochondrial homeostasis and reduced oxidative capacity, although the available data remain equivocal. The release of inflammatory cytokines by tumor is a key mechanism in the initiation of heart failure...
May 2017: Oncology Reports
https://www.readbyqxmd.com/read/28392165/high-fat-mass-associates-with-occurrence-of-targeted-therapy-induced-left-ventricular-ejection-fraction-reduction-in-patients-with-renal-cell-carcinoma
#11
Seyyed Mohammad Reza Kazemi-Bajestani, Harald Becher, Peter Venner, Scott North, Vickie Baracos
BACKGROUND & AIMS: Recent research suggests that variations of skeletal muscle (SM) and fat predict the severity of chemotherapy-induced toxicities in patients with renal cell carcinoma (RCC). Cardio-toxicity has not been evaluated in this context. METHODS: In this study we considered 47 RCC patients who participated in randomized clinical trials of sorafenib or sunitinib (i.e., targeted therapy). To capture cardio-toxicity, multi gated acquisition (MUGA) scan-defined left ventricular ejection fraction (LVEF) tests (at least 3 tests over 1 year of treatment) were abstracted...
March 28, 2017: Clinical Nutrition: Official Journal of the European Society of Parenteral and Enteral Nutrition
https://www.readbyqxmd.com/read/28382098/cardioprotective-effect-of-dexrazoxane-in-patients-with-her2-positive-breast-cancer-who-receive-anthracycline-based-adjuvant-chemotherapy-followed-by-trastuzumab
#12
In-Ho Kim, Ji Eun Lee, Ho-Joong Youn, Byung Joo Song, Byung Joo Chae
PURPOSE: We intended to determine whether dexrazoxane (DZR) is cardioprotective during administration of adjuvant anthracycline-based chemotherapy followed by a 1-year trastuzumab treatment. METHODS: The medical records of 228 patients who underwent surgical resection and received adjuvant chemotherapy with trastuzumab for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer between January 2010 and December 2014 were reviewed. Approximately 25% of patients received DZR prior to each administration of doxorubicin during doxorubicin with cyclophosphamide (AC) chemotherapy...
March 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28381692/malignant-lymphoma-with-cardiac-involvement
#13
Seitaro Terakura, Masaaki Onji, Chisako Iriyama, Tatsunori Goto, Yoko Ushijima, Kazuyuki Shimada, Yuichi Ishikawa, Tetsuya Nishida, Fumihiko Hayakawa, Makoto Murata, Hitoshi Kiyoi
Malignant lymphoma with cardiac involvement is difficult to diagnose and treatment selection decisions can be challenging, because patients usually present with atypical disease involvement and the incidence is low. Herein, we describe the clinical characteristics and courses of three non-Hodgkin lymphoma patients showing cardiac involvement. All three patients were male, ages 32, 74 and 64 years. All three patients had presented with cardiac involvement mainly in the right heart system. We promptly performed needle biopsies for patients 1 and 3, and open-heart biopsy for patient 2, which showed PMBL for patient 1, DLBCL for patients 2 and 3...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/28379383/2d-and-3d-strain-for-detection-of-subclinical-anthracycline-cardiotoxicity-in-breast-cancer-patients-a-balance-with-feasibility
#14
Ciro Santoro, Grazia Arpino, Roberta Esposito, Maria Lembo, Immacolata Paciolla, Cinzia Cardalesi, Giovanni de Simone, Bruno Trimarco, Sabino De Placido, Maurizio Galderisi
Aims: 2D echocardiography is limited for identifying chemotherapy-related cardiotoxicity. This study compared standard echo, 2D, and 3D speckle tracking echocardiography (STE) for detection of subclinical anthracycline (ANT) cardiotoxicity in breast cancer patients. Methods and results: One-hundred consecutive breast cancer patients free of cardiac symptoms were treated by multiple protocols including ANT and cyclophosphamide and/or 5-fluorouracil for 3-4 cycles...
March 31, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28379023/-cardiovascular-complications-of-cancers-and-anti-cancer-therapy
#15
Jiří Vyskočil, Katarína Petráková, Petr Jelínek, Michal Furdek
In our aging population the incidence of cancer is increasing in the elderly. We are thus facing a new challenge especially considering incidence of cardiovascular diseases (CVD) in this patients population. Overall survival of cancer patients has significantly improved therefore cancer has become in many cases a chronic disease. We are about to be treating patients who either may develop a new CVD or their current CVD may deteriorate. Cancer can cause various cardiovascular conditions locally (pressure in mediastinum, effusions) or systemically (increased risk of pulmonary embolism, arrhythmias, carcinoid heart disease)...
2017: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/28377429/circulating-micrornas-potential-markers-of-cardiotoxicity-in-children-and-young-adults-treated-with-anthracycline-chemotherapy
#16
Kasey J Leger, David Leonard, Danelle Nielson, James A de Lemos, Pradeep P A Mammen, Naomi J Winick
BACKGROUND: Biomarkers for early detection of anthracycline (AC)-induced cardiotoxicity may allow cardioprotective intervention before irreversible damage. Circulating microRNAs (miRNAs) are promising biomarkers of cardiovascular disease, however, have not been studied in the setting of AC-induced cardiotoxicity. This study aimed to identify AC-induced alterations in plasma miRNA expression in children and correlate expression with markers of cardiac injury. METHODS AND RESULTS: Candidate plasma profiling of 24 miRNAs was performed in 33 children before and after a cycle of AC (n=24) or noncardiotoxic chemotherapy (n=9)...
April 4, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28369081/rapid-diagnostic-tests-duo-as-alternative-to-conventional-serological-assays-for-conclusive-chagas-disease-diagnosis
#17
Karina E Egüez, Julio Alonso-Padilla, Carolina Terán, Zenobia Chipana, Wilson García, Faustino Torrico, Joaquim Gascon, Daniel-Franz Lozano-Beltran, María-Jesús Pinazo
Chagas disease is caused by the parasite Trypanosoma cruzi. It affects several million people, mainly in Latin America, and severe cardiac and/or digestive complications occur in ~30% of the chronically infected patients. Disease acute stage is mostly asymptomatic and infection goes undiagnosed. In the chronic phase direct parasite detection is hampered due to its concealed presence and diagnosis is achieved by serological methods, like ELISA or indirect hemagglutination assays. Agreement in at least two tests must be obtained due to parasite wide antigenic variability...
April 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28367338/folfox-induced-takotsubo-cardiomyopathy-treated-with-impella-assist-device
#18
Swethika Sundaravel, Abdulah Alrifai, Mohamad Kabach, Waqas Ghumman
Chemotherapy induced cardiotoxicity is becoming increasingly prevalent with several new agents being used recently. The incidence of Takotsubo cardiomyopathy due to 5-fluorouracil based chemotherapeutic regimens like FOLFOX is not uncommon. It is also seen with platinum based chemotherapy. Most of these patients have reversible cardiotoxicity and the cardiac function recovers within a short period with supportive treatment. Here we have a patient who presented with cardiogenic shock after 5 days of receiving FOLFOX regimen for colorectal adenocarcinoma...
2017: Case Reports in Cardiology
https://www.readbyqxmd.com/read/28362511/effect-of-accurate-heart-delineation-on-cardiac-dose-during-the-convert-trial
#19
Nicki Groom, Elena Wilson, Corinne Faivre-Finn
OBJECTIVES: This study investigates the effect of deviation from protocol in heart delineation for the CONVERT Trial ( ClinicalTrials.gov Identifier NCT00433563) quality assurance (QA) programme, and the effect of that on mean cardiac dose and percentage of heart volume receiving ≥5Gy (V5%) and ≥30Gy (V30%). METHODS: CONVERT trial patients with limited-stage small-cell lung cancer (LS SCLC) were randomised to receive 45Gy in 30# BD or 66Gy in 33# OD radiotherapy, with concurrent chemotherapy in both arms...
March 31, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/28353062/self-reported-long-term-cardiac-morbidity-in-breast-cancer-patients-a-retrospective-cohort-study-in-germany-passos-heart-study
#20
Daniel Wollschläger, Hiltrud Merzenich, Lukas Schwentner, Wolfgang Janni, Thomas Wiegel, Detlef Bartkowiak, Achim Wöckel, Marcus Schmidt, Heinz Schmidberger, Maria Blettner
PURPOSE: Improved survival after locoregional breast cancer has increased the concern about late adverse effects after therapy. In particular, radiotherapy was identified as a risk factor for major cardiac events in women treated until the 1990s. While modern radiotherapy with computerized planning based on 3D-imaging can help spare organs at risk, heart exposure may remain substantial. In a retrospective cohort study of women treated for locoregional breast cancer, we investigated whether current radiotherapy is associated with an elevated long-term cardiac morbidity risk...
March 28, 2017: Breast Cancer Research and Treatment
keyword
keyword
106610
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"